A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck

Annals of Oncology

Volumn 24, Issue 3, 2013, Pages 761-769

  Abdul Razak, A R ^a   Soulieres D ^b   Laurie, S A ^c   Hotte, S J ^d   Singh, S ^e   Winquist, E ^f   Chia, S ^g   Tourneau, C L ^a   Nguyen Tan, P F ^b   Chen, E X ^a   Chan, K K ^a   Wang, T ^h   Giri, N ⁱ   Mormont, C ^j   Quinn, S ^k   Siu, L L ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c OTTAWA REGIONAL CANCER CENTRE   (Canada)

^d JURAVINSKI CANCER CENTRE   (Canada)

^e DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^f LONDON HEALTH SCIENCES CENTRE   (Canada)

^g BRITISH COLUMBIA CANCER AGENCY   (Canada)

^h Pfizer Oncology   (United States)

ⁱ Pf Izer Oncology Inc   (United States)

^j PFIZER INC   (United States)

^k Pfizer Research   (United States)

more..

Author keywords

Dacomitinib; Epidermal growth factor receptor; Head and neck; Squamous cell cancer

Indexed keywords

DACOMITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR;

ACNE; ADULT; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEPHARITIS; CONJUNCTIVITIS; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG RESPONSE; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OVERALL SURVIVAL; PARONYCHIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RECURRENT CANCER; SEPSIS; SIDE EFFECT; SKIN FISSURE; STOMATITIS; TREATMENT WITHDRAWAL; VOMITING;

EID: 84874569165     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds503     Document Type: Article

References (37)

1. Argiris A, Karamouzis MV, Raben D et al. Head and neck cancer. Lancet 2008; 371: 1695-1709.
2. Argiris A, Li Y, Forastiere A. Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck. Cancer 2004; 101: 2222-2229.
3. Forastiere AA, Leong T, Rowinsky E et al. Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393. J Clin Oncol 2001; 19: 1088-1095.
4. Forastiere AA, Metch B, Schuller DE et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992; 10: 1245-1251.
5. Razak AR, Siu LL, Le Tourneau C. Molecular targeted therapies in all histologies of head and neck cancers: an update. Curr Opin Oncol 2010; 22: 212-220.
6. Vermorken JB, Trigo J, Hitt R et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007; 25: 2171-2177.
7. Cohen EE, Kane MA, List MA et al. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 2005; 11: 8418-8424.
8. Cohen EE, Rosen F, Stadler WM et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003; 21: 1980-1987.
9. Kirby AM, A'Hern RP, D'Ambrosio C et al. Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer. Br J Cancer 2006; 94: 631-636.
10. Soulieres D, Senzer NN, Vokes EE et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004; 22: 77-85.
11. Stewart JS, Cohen EE, Licitra L et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol 2009; 27: 1864-1871.
12. Wheeler R, Jones D, Sharma P et al. Clinical and molecular phase II study of gefitinib in patients (pts) with recurrent squamous cell cancer of the head and neck (H&N Ca). J Clin Oncol 2005; 23(Suppl.): 5531.
13. Gonzales AJ, Hook KE, Althaus IW et al. Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol Cancer Ther 2008; 7: 1880-1889.
14. Kruser TJ, Wheeler DL. Mechanisms of resistance to HER family targeting antibodies. Exp Cell Res. 2010; 316: 1083-100.
15. Wong TW, Lee FY, Yu C et al. Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signalling. Clin Cancer Res. 2006; 12: 6186-93.
16. Engelman JA, Zejnullahu K, Gale CM et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007; 67: 11924-11932.
17. Sok JC, Coppelli FM, Thomas SM et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 2006; 12: 5064-5073.
18. Janne PA, Boss DS, Camidge DR et al. Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin Cancer Res 2011; 17: 1131-1139.
19. Vermorken JB, Mesia R, Rivera F et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116-1127.
20. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
21. Takahashi T, Boku N, Murakami H et al. Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors. Invest New Drugs 2012; Jan 17 [Epub ahead of print].
22. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10.
23. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
24. Mehvar R. Dependence of time to reach steady-state on the length of dosage interval. Ann Pharmacother 2008; 42: 1518-1519.
25. Boyer M, Blackhall F, Barrios C et al. Overall survival results of a randomized phase 2 trial of PF299804 versus erlotinib in patients with advanced non-small cell ling cancer after failure of chemotherapy. J Thorac Oncol 2011; 6: S318 (abstr. O10.17).
26. Abidoye O, Cohen EE, Wong S. A phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2006; 24: 5568.
27. Seiwert T, Fayatte J, Del Campo J et al. Updated results of a randomized openlabel phase II study exploring BIBW 2992 versus cetuximab in patients with platinum-refractory metastatic/recurrent head and neck cancer (SCCHN). Ann Oncol 2011; 21(Suppl. 8): vii316.
28. Belani CP. The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors. Cancer Invest 2010; 28: 413-423.
29. Kwak E. The role of irreversible HER family inhibition in the treatment of patients with non-small cell lung cancer. Oncologist 2011; 16: 1498-1507.
30. Hamilton M, Wolf JL, Rusk J et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res 2006; 12: 2166-2171.
31. Hughes AN, O'Brien ME, Petty WJ et al. Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. J Clin Oncol 2009; 27: 1220-1226.
32. Pfizer Inc. PF-00299804 Investigator's Brochure. Section 6:72-131. New York, NY: Pfizer Inc. 2010.
33. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578.
34. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11: 21-28.
35. Hoellein A, Pickhard A, von Keitz F et al. Aurora kinase inhibition overcomes cetuximab resistance in squamous cell cancer of the head and neck. Oncotarget 2011; 2: 599-609.
36. Jameson MJ, Beckler AD, Taniguchi LE et al. Activation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells. Mol Cancer Ther 2011; 10: 2124-2134.
37. Rebucci M, Peixoto P, Dewitte A et al. Mechanisms underlying resistance to cetuximab in the HNSCC cell line: role of AKT inhibition in bypassing this resistance. Int J Oncol 2011; 38: 189-200.